Trust Signals
Key takeaways
- A blend total and a component amount are different numbers.
- A component ratio determines how much of each ingredient is present in every measured volume.
- The cited GHK-Cu, Epithalon and BPC-157 studies use different models and routes, so their exposures cannot form a combined dosing chart.
- The examples below calculate composition and volume with a reverse check for each ingredient.
What determines a GLOW peptide amount?
For a measured volume, each component amount equals its labeled vial amount divided by final solution volume, then multiplied by the measured volume. A combined vial total gives only the total concentration. It cannot reveal how much GHK-Cu, BPC-157 or another ingredient is present without the component split.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →On this page
- Study exposures versus a blend schedule
- Component concentration chart
- Why the blend ratio matters
- Reverse-check an amount and volume
- Common questions
Start with the actual formulation
This guide's earlier version treated GHK-Cu, Epithalon and BPC-157 as a standard GLOW stack. A name is not evidence of a standard composition. An ingredient not listed on the actual vial should not be silently included in its calculation. Ratios, total amounts and final volumes need to be read separately.
What the named studies contribute to a dosage question
| Component | Primary record | Exposure actually studied | What it does not supply |
|---|---|---|---|
| GHK-Cu | Maquart 1993 | Local injections in rat wound chambers | A human blend injection dose or cycle |
| GHK-Cu | NCT07437586 | Topical 0.1% w/w gel; planned 60 people; no posted results on October 3, 2026 | A completed efficacy result or subcutaneous regimen |
| Epithalon | Khavinson 2003 | Human fetal fibroblast culture; telomerase activity and telomere measurements | A trial of people receiving a 5-10 mg daily cycle |
| BPC-157 | Lee and Burgess 2025 | Two adults with prior intravenous exposure; 10 mg IV on day one and 20 mg IV on day two | A controlled skin-outcome trial or subcutaneous blend schedule |
The BPC-157 report observed no reported side effects or measured biomarker changes in its two participants. That observation does not give a treatment-response percentage or establish a blend's effectiveness. The Epithalon paper reports a cell-culture experiment, even though its title refers to human cells. A cell result is not a human clinical dosing study.
A component concentration chart with explicit inputs
The following vial is hypothetical: 10 mg ingredient A, 5 mg ingredient B and 5 mg ingredient C, for 20 mg total. Letters avoid presenting this arithmetic example as a recommended peptide combination. The compared sample is always 0.1 mL.
| Final volume | A concentration | B concentration | C concentration | Total concentration | Amounts in 0.1 mL: A + B + C |
|---|---|---|---|---|---|
| 1 mL | 10 mg/mL | 5 mg/mL | 5 mg/mL | 20 mg/mL | 1 + 0.5 + 0.5 = 2 mg |
| 2 mL | 5 mg/mL | 2.5 mg/mL | 2.5 mg/mL | 10 mg/mL | 0.5 + 0.25 + 0.25 = 1 mg |
| 2.5 mL | 4 mg/mL | 2 mg/mL | 2 mg/mL | 8 mg/mL | 0.4 + 0.2 + 0.2 = 0.8 mg |
| 4 mL | 2.5 mg/mL | 1.25 mg/mL | 1.25 mg/mL | 5 mg/mL | 0.25 + 0.125 + 0.125 = 0.5 mg |
| 5 mL | 2 mg/mL | 1 mg/mL | 1 mg/mL | 4 mg/mL | 0.2 + 0.1 + 0.1 = 0.4 mg |
At a final 2 mL, A is 5 mg/mL and B and C are each 2.5 mg/mL. A 0.1 mL sample contains 0.5 mg A, 0.25 mg B and 0.25 mg C. Their sum is 1 mg, matching the total concentration of 10 mg/mL multiplied by 0.1 mL. Calling that sample 1 mg of each component would triple the total.
Same total amount, different ingredient exposure
| Vial example, both 20 mg total | Final volume | Amount A in 0.1 mL | Amount B in 0.1 mL | Amount C in 0.1 mL |
|---|---|---|---|---|
| 10 mg A + 5 mg B + 5 mg C | 2 mL | 0.5 mg | 0.25 mg | 0.25 mg |
| 16 mg A + 2 mg B + 2 mg C | 2 mL | 0.8 mg | 0.1 mg | 0.1 mg |
Both examples contain 1 mg total in the sample. In the second, A is 60% higher than in the first, while B and C are each 60% lower. These percentages describe ingredient amounts, not changes in effectiveness. Increasing the volume of a fixed blend raises every component together; it cannot independently adjust one component.
Reverse-check an amount against every component
Using the first vial at 2 mL, a hypothetical amount of 0.75 mg A corresponds to 0.75 divided by 5 = 0.15 mL. That volume also contains 0.375 mg B and 0.375 mg C, for a total of 1.5 mg. A reverse check returns 0.15 times 5 = 0.75 mg A. It does not establish that 0.75 mg is a suitable dose.
On a U-100 scale, 0.15 mL corresponds to 15 marked units. These are volume markings, not milligrams. Changing final volume requires recalculating all three concentrations before reusing any previous scale number.
Why concentration math cannot determine a cycle
A dose amount, administration interval and cycle duration answer different questions. The cited studies do not validate a combined 20-day cycle, a six-week washout or an 8-12-week injection schedule. A calculator can reproduce the concentration formula; it cannot manufacture the missing comparative outcome data.
Quantity, identity and stability are separate measurements
A total vial amount, a component assay and an HPLC area percentage should not be collapsed into one number. For example, an area result of 90% does not on its own show that a nominal 5 mg vial contains exactly 4.5 mg. That conclusion needs quantitative assay data and the stated calculation basis.
Likewise, a visual change cannot tell you the amount of each component remaining. The named trials do not provide a universal storage interval for every blend.
Common questions
Does 20 mg of GLOW mean 20 mg of each ingredient?
No. If 20 mg is the blend total, the component amounts must add to 20 mg. The example above uses 10 + 5 + 5 mg.
Can two 20 mg vials have different component concentrations?
Yes. Both the ingredient ratio and final volume determine individual concentrations.
Can more water change the ingredient ratio?
It lowers every concentration together. It does not change the labeled ratio of component amounts.
Is 340.38 the molecular weight of GHK-Cu?
It is the copper-free GHK value in PubChem CID 73587. See the chemical identity comparison for the separate copper-containing record.
Primary sources
- Maquart et al. 1993, PMID 8227353
- ClinicalTrials.gov, NCT07437586
- Khavinson et al. 2003, PMID 12937682
- Lee and Burgess 2025, PMID 40131143
Disclaimers
Platform: FormBlends is an informational and educational platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before beginning any peptide protocol.
Research Compound: The peptides described on this page are research compounds or compounded medications. They are not FDA-approved drugs for the indications discussed. Their sale for human use may be subject to regulatory restrictions that vary by jurisdiction. FormBlends does not sell or supply peptides.
Results: Individual outcomes vary. The evidence grades in this article reflect the current state of published literature. Positive signals in animal or in-vitro studies do not guarantee equivalent effects in humans at the doses described.
Trademarks: "Glow Protocol" and related terms may be trademarks of their respective compounding or commercial entities. Use of these terms on this page is descriptive
Related peptide guides
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →